Literature DB >> 17353947

Huntington's disease: clinical characteristics, pathogenesis and therapies.

Ken Nakamura1, Michael J Aminoff.   

Abstract

Huntington's disease is a devastating disorder with no known cure. The disease results from an expanded sequence of CAG repeats in the huntingtin gene and leads to a movement disorder with associated cognitive and systemic deficits. Huntington's disease is diagnosed by genetic testing and disease progression can be followed with a variety of imaging modalities. The accumulation of aggregated huntingtin with associated striatal degeneration is evident at autopsy. The pathophysiology of Huntington's disease remains unknown, although protein aggregation, excitotoxicity, deficits in energy metabolism, transcriptional dysregulation and apoptosis may all be involved. Current pharmacologic therapy for Huntington's disease is limited and exclusively symptomatic. However, the disease is being heavily researched, and a wide range of disease-modifying therapies is currently under development. The efficacy of these therapies is being evaluated in transgenic models of Huntington's disease and in preliminary clinical trials. Copyright (c) 2007 Prous Science. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17353947     DOI: 10.1358/dot.2007.43.2.1050788

Source DB:  PubMed          Journal:  Drugs Today (Barc)        ISSN: 1699-3993            Impact factor:   2.245


  7 in total

Review 1.  MicroRNA implications across neurodevelopment and neuropathology.

Authors:  Sabata Martino; Ilaria di Girolamo; Antonio Orlacchio; Alessandro Datti; Aldo Orlacchio
Journal:  J Biomed Biotechnol       Date:  2009-10-13

Review 2.  Treatment of Huntington's disease.

Authors:  Samuel Frank
Journal:  Neurotherapeutics       Date:  2014-01       Impact factor: 7.620

3.  Intrabodies binding the proline-rich domains of mutant huntingtin increase its turnover and reduce neurotoxicity.

Authors:  Amber L Southwell; Ali Khoshnan; Denise E Dunn; Charles W Bugg; Donald C Lo; Paul H Patterson
Journal:  J Neurosci       Date:  2008-09-03       Impact factor: 6.167

Review 4.  Advances in the pharmacological management of Huntington's disease.

Authors:  Samuel Frank; Joseph Jankovic
Journal:  Drugs       Date:  2010-03-26       Impact factor: 9.546

5.  Tetrabenazine: the first approved drug for the treatment of chorea in US patients with Huntington disease.

Authors:  Samuel Frank
Journal:  Neuropsychiatr Dis Treat       Date:  2010-10-05       Impact factor: 2.570

6.  Atg4b-dependent autophagic flux alleviates Huntington's disease progression.

Authors:  Catia C Proenca; Natacha Stoehr; Mario Bernhard; Shanon Seger; Christel Genoud; Ana Roscic; Paolo Paganetti; Shanming Liu; Leon O Murphy; Rainer Kuhn; Tewis Bouwmeester; Ivan Galimberti
Journal:  PLoS One       Date:  2013-07-08       Impact factor: 3.240

7.  Calcium signaling in neurodegeneration.

Authors:  Philippe Marambaud; Ute Dreses-Werringloer; Valérie Vingtdeux
Journal:  Mol Neurodegener       Date:  2009-05-06       Impact factor: 14.195

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.